Chapter 81 – Caffeolyquinic Acid Protects against Alzheimer’s Disease through Inhibition of Amyloid Beta-Induced Toxicity
Abstract
Although
several drugs for Alzheimer's disease are now available, none of them
are able to slow down, halt, or cure the neurodegeneration in
Alzheimer's disease. In this respect, inhibition of amyloid beta (Aβ)
aggregation is becoming an attractive pharmacological therapeutic
strategy. Some research has demonstrated that natural polyphenols might
be a potential strategy for the prevention or treatment of Alzheimer's
disease. This chapter examines the effect of caffeoylquinic acid (CQA)
on Alzheimer's disease at the in vitro level. Human neuroblastoma
SH-SY5Y cells treated with Aβ(1–42) were used as the in vitro model. CQA treatments significantly reversed Aβ(1–42)-induced
neurotoxicity in SH-SY5Y cells, improved ATP, synthesis and reduced the
generation of reactive oxygen species induced by Aβ(1–42). Moreover, thioflavin-T (Th-T) fluorescence assay demonstrated that CQA may prevent the aggregation of Aβ1–42
in a dose-dependent manner. These results are in concordance with our
previous studies showing that oral administration of CQA significantly
improved memory deficit in senescence-accelerated prone mice 8.
Keywords
- Alzheimer's disease;
- Amyloid β aggregation;
- Caffeolquinic acid;
- Neuroprotection
List of Abbreviations
- CQA
- Caffeoylquinic acid
- Aβ
- Amyloid beta
- ATP
- Adenosine triphosphate
- Th-T
- Thioflavin-T
- QA
- Quinic acid
- CNS
- Central nervous system
- ROS
- Reactive oxygen species
- APP
- Amyloid β-protein precursor
- ALS
- Amyotrophic lateral sclerosis
- SAMP
- Senescence-accelerated mouse prone
- WHO
- World Health Organization
- ATCC
- American Type Culture Collection
- PBS
- Sodium phosphate buffer
Copyright © 2015 Elsevier Inc. All rights reserved.
